Cowen Starts Allena Pharmaceuticals (ALNA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq slides over 1% as Alphabet results revive AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Wedbush Starts Allena Pharmaceuticals (ALNA) at Outperform; Sees $3B Blockbuster Sales Potential from ALLN-177
November 27, 2017 6:32 AM ESTWedbush initiates coverage on Allena Pharmaceuticals (NASDAQ: ALNA) with a Outperform rating and a price target of $30.00.
Analyst Liana Moussatos sees ALNA as an opportunity to invest in oral enzyme treatments for patients with severe metabolic and kidney disorders.
They project cash... More
Jefferies Starts Allena Pharmaceuticals (ALNA) at Buy
November 27, 2017 2:08 AM ESTJefferies initiates coverage on Allena Pharmaceuticals (NASDAQ: ALNA) with a Buy rating and a price target of $22.00.
Analyst Matt Andrews believes the company's drug, ALLN-177, will be "The Next Big Metabolic Enzyme Blockbuster."
For an analyst ratings summary and ratings history on... More



